Highlights Q32 Bio Inc.

Equities

QTTB

US7469641051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
30.36 ^USD	-2.06%		+11.91%	+177.41%

May. 09	Q32 Bio Inc. Provides Corporate Update	CI
Apr. 11	Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Q32 Bio Inc. Provides Corporate Update	May. 09	CI
Q32 Bio Inc. Appoints Lee Kalowski as Chief Financial Officer	Apr. 03	CI
Q32 Bio Inc. completed the acquisition of Homology Medicines, Inc. from 5AM Venture Management, LLC, Arch Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P. managed by Arch Venture Partners, L.P., Pfizer Inc. and TLS Beta Pte. Ltd. in a reverse merger transaction.	Mar. 24	CI
Homology Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Homology Medicines, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Homology Medicines, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Homology Medicines Announces First Data from IND-Enabling Studies with GTx-Mab Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, At the ASGCT Annual Meeting	23-05-16	CI
Homology Medicines, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Homology Medicines, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-09	CI
HOMOLOGY MEDICINES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-09	AQ
Homology Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy	23-02-22	CI
Homology Medicines, Inc. Provides Update on pheEDIT and juMPStart Clinical Trials	23-01-04	CI
Homology Medicines, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
HOMOLOGY MEDICINES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-08-15	AQ
Homology Medicines, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Homology Medicines Announces Optimized, in Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy	22-08-11	CI
Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver	22-07-05	CI
Homology Medicines, Inc. Announces FDA Lifted Clinical Hold on Phenix Gene Therapy Trial for Pku	22-06-13	CI
HOMOLOGY MEDICINES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-05-16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Q32 Bio Inc.

Equities

QTTB

US7469641051

Highlights

Filters